NEWS | BEAM Alliance


Polyphor presents new data at ECCMID from its lead antibiotic murepavadin and the new OMPTA POL7306

Allschwil, Switzerland, April 17, 2019

  • Murepavadin to be more potent than standard of care anti-Pseudomonas antibiotics against multidrug and colistin resistant Pseudomonas aeruginosa isolates
  • Clinical development candidate POL7306 demonstrates potent bactericidal activity against a large collection of Gram-negative organisms including WHO priority 1 Gram-negative pathogens and shows a low propensity of resistance development invitro.

Polyphor AG (SIX: POLN) presented new data on its lead clinical antibacterial candidate, murepavadin, currently in Phase III, and its preclinical medium-spectrum anti Gram-negative antibiotic POL7306 at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands.

Full PR available here